MTOR and neoplasm: We found that AZD5363 drastically inhibited E2-enhanced expression of p-4Ebp1, p-mTor, and p-Gsk3β, and that of Vim and p-Fra1 (Fig. 6a), suggesting that AZD5363 efficiently suppresses estrogen-enhanced Akt pathway and EMT program in Brca1 deficient tumor cells.